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Abstract
Introduction: In many countries, mortality due to suicide is higher among people living with HIV than in the general popula-
tion. We aimed to analyse trends in suicide mortality before and after the introduction of triple combination antiretroviral
therapy (cART), and to identify risk factors associated with death from suicide in Switzerland.
Methods: We analysed data from the Swiss HIV Cohort Study from the pre-cART (1988-1995), earlier cART (1996-2008)
and later cART (2009-2017) eras. We used multivariable Cox regression to assess risk factors for death due to suicide in the
ART era and computed standardized mortality ratios (SMRs) to compare mortality rates due to suicide among persons living
with HIV with the general population living in Switzerland, using data from the Swiss National Cohort.
Results and Discussion: We included 20,136 persons living with HIV, of whom 204 (1.0%) died by suicide. In men, SMRs
for suicide declined from 12.9 (95% CI 10.4-16.0) in the pre-cART era to 2.4 (95% CI 1.2-5.1) in the earlier cART and 3.1
(95% CI 2.3-4.3) in the later cART era. In women, the corresponding ratios declined from 14.2 (95% CI 7.9-25.7) to 10.2
(3.8-27.1) and to 3.3 (95% CI 1.5-7.4). Factors associated with death due to suicide included gender (adjusted hazard ratio
0.58 (95% CI 0.38-0.87) comparing women with men), nationality (1.95 (95% CI 1.34-2.83) comparing Swiss with other),
Centers for Disease Control and Prevention clinical stage (0.33 (95% CI 0.24-0.46) comparing stage A with C), transmission
group (2.64 (95% CI 1.71-4.09) for injection drug use and 2.10 (95% CI 1.36-3.24) for sex between men compared to
other), and mental health (2.32 (95% CI 1.71-3.14) for a history of psychiatric treatment vs. no history). There was no asso-
ciation with age.
Conclusions: Suicide rates have decreased substantially among people living with HIV in the last three decades but have
remained about three times higher than in the general population since the introduction of cART. Continued emphasis on sui-
cide prevention among men and women living with HIV is important.
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1 | INTRODUCTION
Depression, anxiety and other mental health problems are
common among people living with HIV, and more common
than in the general population or among comparable HIV-
negative people [1-4]. In the era before the advent of triple
combination antiretroviral therapy (cART), several studies
showed that HIV infection was also associated with suicide
[5,6]. In Switzerland, suicides accounted for 6% of deaths
among people living with HIV [7]. An analysis of the Swiss
HIV Cohort Study (SHCS) found that during the years 1988
to 2008, suicide rates decreased somewhat with the introduc-
tion of cART, but remained above the rate observed in the
general population. A recent study in the UK also found that
in the cART era, HIV-related suicide rates were higher than in
the general population [8].
A French study reported that risk factors for suicide among
persons living with HIV included a history of intravenous drug
use (IDU), alcohol abuse and a history of depression or
attempted suicide [9]. In the Swiss study [10], a history of
treatment by a psychiatrist was a predictor of suicide both
before and after the introduction of cART, while factors such
as advanced clinical stage and gender were important only
before cART was introduced. Several antiretroviral drugs have
been associated with adverse effects that could lead to suicide
ideation [11], including efavirenz or dolutegravir, drugs which
are widely used and recommended by the World Health
Organization [12-14].
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In this article, we update the previous analysis [10] of mor-
tality rates due to suicide in persons living with HIV and the
general population in Switzerland, to explore risk factors and
time trends in suicide over almost 30 years, from the pre-
cART era up to recent years.
2 | METHODS
We analysed suicide rates and risk factors in the SHCS. Rates
of suicide in people living with HIV were compared to suicide
rates in the general Swiss population using data from the
Swiss National Cohort (SNC). Throughout this study, the out-
come of interest was death by suicide. No data were available
on suicide ideation, or suicide attempts.
2.1 | Data sources
The SHCS (www.shcs.ch) is an ongoing multicenter study
involving people living with HIV aged 18 years or older [15].
The study collects key patient information such as demo-
graphic characteristics, information on HIV-related diseases
and treatments, and laboratory measurements. This informa-
tion is collected at enrollment and at six-monthly follow-up
visits. The cohort is estimated to cover around 45% of the
cumulative number of HIV infections notified to the Swiss
health authorities, 69% of people living with AIDS and 75% of
individuals receiving antiretroviral treatment [15].
The SNC (www.swissnationalcohort.ch) is a national longitu-
dinal study on mortality, based on the probabilistic linkage of
individual-based data from 1990 and 2000 nationwide cen-
suses with Federal mortality records [16]. The cohort consists
of 6.9 million census participants in 1990 and 7.3 million in
2000.
2.2 | Data analysis
We compared characteristics of participants enrolled in the
SHCS during the pre-cART era (1988-1995), earlier cART
(1996-2008), and later cART era (2009-2017) between those
who died by suicide (code ‘suicide’ in the SHCS, ICD-8 codes
E950-959 and ICD-10 codes X60-X84 in the SNC) and those
who did not. Completeness and quality of mortality data in
the SHCS are high [7]. For each year, we calculated the
expected number of suicides, per sex and per five-year age
group, based on rates from the SNC data. From this we
derived standardized mortality ratios (SMRs) for each ART
era, assuming a Poisson distribution. We split the earlier cART
era further into sub-periods 1996-1998 and 1999-2008. We
analysed predictors for suicide in the SHCS using multivari-
able Cox regression. This was done separately for the pre-
cART, earlier cART and later cART eras. We included the
following predictors in the models: age at enrollment (per
10 years increase), gender, nationality (Swiss/other) and mode
of transmission (injection drug use, men having sex with men,
or other), Centers for Disease Control and Prevention (CDC)
clinical stage as a time updated variable (A, B, or C), and prior
treatment by a psychiatrist as a time-updated variable. We
used interaction tests to assess differences in associations
between risk factors and suicide across time periods. We car-
ried out a separate Cox regression analysis covering the
period 2002 to 2017, which included socio-economic factors:
education (at enrollment, tertiary vs. other), living alone (time-
updated), and unemployment (time-updated, defined as 50%
or more of revenue provided by unemployment benefits since
previous visit). We verified the Cox proportional hazards
assumptions using Schoenfeld residual tests. In order to exam-
ine to what extent the trends observed were driven by speci-
fic patient groups, we recalculated SMRs after excluding
individuals who had contracted HIV through IDU or through
sex between men, and individuals treated by a psychiatrist at
enrollment.
We identified predictors for efavirenz and dolutegravir use
in patients on cART, using multivariate logistic regressions.
Models were adjusted for age at enrollment, sex, nationality,
transmission group, CDC clinical stage at enrollment, and his-
tory of psychiatric treatment at enrollment. Finally, we exam-
ined the association between efavirenz-based therapy (time-
updated) and suicide among patients on cART, adjusting for
the factors mentioned above. We performed a similar analysis
for dolutegravir-based therapy in the late cART era. Results
are presented as adjusted hazard ratio (aHR) or adjusted odds
ratio (aOR), with 95% confidence intervals.
3 | RESULTS AND DISCUSSION
3.1 | Characteristics of study population
We included 20,139 patients in the analysis. Participants
enrolled in the later cART era were older and less likely to be
women, Swiss nationals, or to have acquired HIV through
injection drug use compared to those enrolled in the earlier
cART era; they were also less likely to be in an advanced
stage of HIV and more likely to be treated by a psychiatrist at
enrollment (Table 1).
3.2 | Trends in suicide rates in people living with
HIV and the general population
Overall, 204 people with HIV died by suicide over 184,402 per-
son-years, for a rate of 110.6 per 100,000 person-years (95%
CI 96.4-126.9). Figure 1 shows trends in rates of suicide in
comparison to the general Swiss population. In men living with
HIV, crude suicide rates decreased from 446.1 per 100,000
person-years (95% CI 358.8-554.7) in the pre-cART era, to
99.1 (95% CI 51.6-190.5) in the two years following the intro-
duction of cART, then to 72.4 (95% CI 55.3-96.4) in the later
cART era. In women, the corresponding decline was from 148.9
(95% CI 82.5-268.9), to 74.9 (95% 24.2-232.3), then to 34.0
(95% CI 17.0-68.1). Crude rates also declined in the general
Swiss population from the pre-cART era to the later cART era:
from 32.6 (95% CI 32.1-33.2) to 19.5 (95% CI 19.0-20.1) in
men, and from 12.9 (95% CI 12.6-13.2) to 6.8 (95% CI 6.5-7.1)
in women. The SMRs comparing men living with HIV with men
from the general population decreased from 12.9 (95% CI
10.4-16.0) in the pre-cART era, to 2.4 (95% CI 1.2-5.1) after
the introduction of cART, after which it increased slightly to 3.1
(95% CI 2.3-4.3) in the later cART era. In women, the corre-
sponding ratios declined from 14.2 (95% CI 7.9-25.7) to 10.2
(3.8-27.1), and to 3.3 (95% CI 1.5-7.4).
The biggest drop in rates was thus observed after cART
was introduced in 1996. Since then no important decline in
Ruffieux Y et al. Journal of the International AIDS Society 2019, 22:e25339
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25339/full | https://doi.org/10.1002/jia2.25339
2
rates was observed in men, despite the more tolerable, effica-
cious and simpler antiretroviral drug regimens that became
available in the later cART period [17]. In contrast, rates con-
tinued to decline in women. Rates also decreased in the gen-
eral population, and the suicide rates among people living with
HIV continued to be over three times higher compared to the
general Swiss population, both in women and men.
Results were similar after excluding men who have sex with
men (MSM) or patients being treated by a psychiatrist at
enrollment (Figure 2). When excluding individuals who con-
tracted HIV through IDU, results were similar in men,
whereas in women the SMR was close to 1 in the later cART
period, with wide confidence intervals.
3.3 | Risk factors for suicide in people living with HIV
Participants of the SHCS who died by suicide were more
likely to be male, of Swiss origin, have a history of IDU and
have a lower CD4 cell count at the last visit than patients
who did not die by suicide. In the two cART eras, but not
in the pre-cART era, those who died by suicide were also
more likely to be in a more advanced clinical stage, and
more likely to have been in psychiatric treatment (Table 1).
Table 2 summarizes risk factors for suicide. All variables
except age were important predictors of suicide over the
entire study period. When analysed by period, psychiatric
treatment was a strong predictor for suicide in all three
eras, with HRs ranging from 2.41 to 3.67. Men and Swiss
nationals had higher rates of suicide than women and other
nationals, and patients with less advanced disease (stage A)
had lower rates than those with more advanced disease,
but these associations did not reach conventional levels of
statistical significance for each ART era. When formally
assessing trends across periods using interaction tests, there
was little evidence that associations with risk factors chan-
ged (p values from interaction tests all > 0.1), in contrast to
the previous analysis of the SHCS data up to the year
2008 [10].
Table 1. Characteristics of participants in the Swiss HIV Cohort during the pre-cART (1988-1995), earlier cART (1996-2008), and
later cART (2009-2017) eras, by whether or not they died by suicide
Variable
Pre-cART era Earlier cART era Later cART era
Died by suicide Died by suicide Died by suicide
Yes (N = 92) No (N = 7641) Yes (N = 63) No (N = 7793) Yes (N = 49) No (N = 4498)
Female 11 (12.0) 2040 (26.7) 14 (22.2) 2427 (31.1) 8 (16.3) 1052 (23.4)
Median age at enrollment (years) 31 (27-39) 31 (27-37) 34 (29-44) 36 (30-43) 36 (30-43) 39 (31-47)
Mode of transmission
Intravenous drug use 42 (45.7) 3159 (41.3) 24 (38.1) 1357 (17.4) 14 (28.6) 228 (5.1)
Sex between men 41 (44.6) 2536 (33.2) 26 (41.3) 2806 (36.0) 25 (51.0) 2355 (52.4)
Heterosexual contact 9 (9.8) 1714 (22.4) 10 (15.9) 3282 (42.1) 9 (18.4) 1620 (36.0)
Other 0 (0.0) 232 (3.0) 3 (4.8) 348 (4.5) 1 (2.0) 641 (6.5)
CDC clinical stage
At enrollment
A 50 (54.3) 4421 (57.9) 40 (63.5) 5258 (67.5) 33 (67.4) 3433 (76.3)
B 24 (26.1) 1633 (21.4) 11 (17.5) 1258 (16.1) 6 (12.2) 448 (10.0)
C 18 (19.6) 1587 (20.8) 12 (19.1) 1277 (16.4) 10 (20.4) 617 (13.7)
At last visit
A 25 (27.2) 1563 (20.5) 23 (36.5) 4123 (52.9) 21 (42.9) 3292 (73.2)
B 27 (29.3) 1843 (24.1) 18 (28.6) 1735 (22.3) 8 (16.3) 520 (11.6)
C 40 (43.5) 4235 (55.4) 22 (34.9) 1935 (24.8) 20 (40.8) 686 (15.2)
Psychiatric treatment
At enrollment 10 (10.9) 400 (5.2) 12 (19.1) 599 (7.7) 4 (8.2) 457 (10.2)
Ever 19 (20.7) 2109 (27.6) 33 (52.4) 2819 (36.2) 28 (57.1) 1148 (25.5)
CD4 cell count (cells/lL)
At enrollment
Count available 80 (87.0) 6660 (87.2) 61 (96.8) 7780 (99.8) 48 (98.0) 4483 (99.7)
Median count 307 (125-560) 306 (120-540) 370 (195-562) 339 (185-526) 418 (194-635) 420 (257-608)
At last visit
Count available 81 (88.0) 7154 (93.6) 62 (98.4) 7736 (99.3) 48 (98.0) 4448 (98.9)
Median count 180 (40-440) 204 (30-504) 286 (152-532) 580 (382-799) 477 (284-712) 635 (461-852)
Numbers (%) or medians (IQR) are shown.
cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile range.
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We found that living alone was associated with higher sui-
cide rates (aHR 1.83, 95% CI 1.17-2.87) during 2002-2017,
independently of the other factors. We found no such associa-
tion with education and unemployment. Furthermore, adjust-
ing for these socio-economic factors did not noticeably alter
the estimated effect of the other variables on suicide rates.
Among individuals on cART, those with a history of psychi-
atric treatment at enrollment were less likely to be prescribed
efavirenz compared to those without (aOR 0.70; 95% CI 0.60-
0.81). Similarly, participants with a history of IDUs were less
likely to be prescribed efavirenz than patients in the other
transmission groups (aOR 0.58; 95% CI 0.51-0.65). Women
were less likely to receive efavirenz than men (aOR 0.87; 95%
CI 0.79-0.95, comparing women to men). Dolutegravir was
more likely to be prescribed to Swiss nationals than to non-
Swiss (aOR 1.28; 95% CI 1.10-1.49), and to patients with
advanced CDC clinical stage. We found no evidence that efa-
virenz-based therapy was associated with suicide in HIV-posi-
tive people on cART (aHR 1.00, 95% CI 0.66-1.52). The
analysis for dolutegravir-based cART was similarly inconclusive
(aHR 0.38, 95% CI 0.09-1.57).
Male gender, Swiss nationality, a history of injection drug
use, sexual contact between men, or of treatment by a psychi-
atrist and being at a more advanced clinical stage were thus
risk factors for suicide among HIV-positive people living in
Switzerland, confirming risk factors found in earlier studies
from France and Denmark [9,18]. Of note, there was little evi-
dence that the strength of the associations with these risk
factors changed over the study period, in contrast to a previ-
ous analysis of the SHCS including data up to the year 2008
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Figure 1. Suicide in the Swiss HIV Cohort Study and the general population, 1988-2017, by gender.
Rates in the cohort (upper panel), the general population (middle panel) and standardized mortality ratios (SMRs; bottom panel). Rates and SMRs
with 95% confidence intervals are shown.
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[10]. The lack of an association with efavirenz supports the
notion that in clinical practice, efavirenz may be less fre-
quently used in patients with underlying psychiatric conditions
[19].
3.4 | Strengths and limitations
Strengths of this study include the large number of patients
followed up during almost 30 years. The SHCS enrolled
about 45% of all patients with HIV and about 70% of
patients with AIDS in the country [15], and results are
likely to be applicable to Switzerland and similar countries.
Another strength was the inclusion of data from the SNC
[16], which allowed us to compare time trends in suicide
rates and risk factors between HIV-infected patients and
the general population.
Our study has several limitations. We standardized the
SMRs with respect to age, calendar year, and gender, but not
with respect to sexual orientation, IDU, or other lifestyle fac-
tors that could affect suicide rates. Another limitation of our
study is the possible misclassification of suicide and death by
accidental overdose in participants with a history of IDU. Sui-
cide attempts were not collected. Furthermore, we could not
distinguish between suicide and assisted suicide. The latter is
legal in Switzerland under certain conditions [20], but is not
specifically reported in the SHCS. Assisted suicide rates have
increased in Switzerland over the past decade, but this
increase mainly concerned the elderly [21,22].
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Figure 2. Standardized mortality ratios (SMRs) comparing suicide rates in the Swiss HIV Cohort Study and the general population, after
excluding individuals who had contracted HIV through intravenous drug use (upper panel), or men who had contracted HIV through sex
with other men (middle panel), or patients undergoing psychiatric treatment at enrollment (bottom panel).
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3.5 | Interpretation and context
Sexual orientation, substance use and other mental health
problems may be distal common causes of HIV infection
and suicide, with HIV-related stigma, addiction, and depres-
sion on the proximal causal pathway to suicide [23]. These
variables were not available for the general population in
this study, precluding, for example, comparisons of suicide
rates in MSM with heterosexual men. Meta-analysis of
cross-sectional studies of lifetime suicide attempts showed
that the risk was higher in lesbian, gay and bisexual peo-
ple than heterosexual people, and particularly high in gay
and bisexual men [24]. A Danish study [25], but not a
study from the United States of America [26], showed that
mortality from suicide was higher in MSM than in hetero-
sexual men. Our sensitivity analyses excluding people who
acquired HIV through IDU or through MSM are compati-
ble with the hypothesis that the increased risk of suicide
in HIV-positive women may mainly be driven by IDU,
whereas in men it may be related to both to IDU and the
higher incidence in MSM, mediated by stigma, isolation
and discrimination. In a French survey, poor socio-eco-
nomic status was shown to be associated with an
increased risk of suicide attempts in women with HIV [27],
while loneliness and discrimination were also associated
with a higher risk of suicide, independently of sex and sex-
ual orientation [28].
How do suicide rates in people with HIV compare with
those suffering from other conditions? Suicide rates have been
shown to be higher in people with conditions associated with
chronic pain or poor prognosis [29], including patients with
cancer [30], neurological diseases such as amyotrophic lateral
sclerosis [31] or progressive multiple sclerosis [32]. An analy-
sis of the Surveillance, Epidemiology and End Results database
1973 to 2013 in the United States of America showed that
SMRs for suicide ranged from 1.18 for prostate cancer to
4.17 for lung cancer [33]. SMRs decreased over time for all
cancers, but particularly for lung cancer. An increased risk of
suicide has also been shown for several neurological disorders,
including multiple sclerosis, stroke, Huntington disease and
epilepsy, whereas Parkinson’s disease may be associated with
a reduced risk of suicide [34]. Of note, in a nationwide sample
of people with HIV on cART in the Netherlands, poor mental
health was more common in people living with HIV compared
to people living with diabetes or rheumatoid arthritis [35].
4 | CONCLUSIONS
Since the introduction of cART in 1996, mortality rates due
to suicide have significantly decreased in men and women
living with HIV in Switzerland, but no important improve-
ments in SMRs were observed in men in more recent
years, despite the advent of more tolerable, more effica-
cious and less complex antiretroviral drug regimens in the
later cART period [17]. Furthermore, it is noteworthy that
the SMRs were larger than those reported in the literature
for conditions with worse prognosis. In Switzerland and
elsewhere, there is a continued need to monitor depression,
suicidality in HIV-positive people, and to develop tailored
suicide prevention programs aimed at reducing suicide risk
in people living with HIV.
Table 2. Risk factors for suicide in the Swiss HIV Cohort Study during the pre-cART (1988-1995), earlier cART (1996-2008) and
later cART (2009-2017) eras
Variable
Pre-cART era Earlier cART era Later cART era
All eras
aHR (95% CI) aHR (95% CI) aHR (95% CI) aHR (95% CI) p
Age (per 10-year increase) 1.06 (0.81-1.38) 1.29 (0.99-1.70) 1.17 (0.85-1.60) 0.98 (0.84-1.15) 0.79
Sex 0.009
Male 1 1 1 1
Female 0.46 (0.23-0.89) 0.84 (0.43-1.64) 0.62 (0.26-1.48) 0.58 (0.38-0.87)
Origin 0.001
Other 1 1 1 1
Swiss 1.33 (0.75-2.36) 2.68 (1.21-5.94) 1.23 (0.63-2.38) 1.95 (1.34-2.83)
Risk group <0.001
Other 1 1 1 1
Men having sex with men 2.23 (1.05-4.74) 1.72 (0.82-3.61) 1.82 (0.80-4.16) 2.10 (1.36-3.24)
Injection drug use 2.02 (0.97-4.23) 1.85 (0.88-3.86) 2.65 (1.09-6.42) 2.64 (1.71-4.09)
CDC clinical stage <0.001
C 1 1 1 1
B 0.63 (0.38-1.03) 0.63 (0.34-1.18) 0.35 (0.16-0.81) 0.55 (0.39-0.78)
A 0.28 (0.17-0.47) 0.57 (0.31-1.05) 0.55 (0.28-1.06) 0.33 (0.24-0.46)
Psychiatric treatment <0.001
No 1 1 1 1
Yes 2.45 (1.45-4.14) 3.63 (2.14-6.16) 2.42 (1.32-4.43) 2.32 (1.71-3.14)
aHR, adjusted hazard ratio; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention.
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APPENDIX
The members of the Swiss HIV Cohort Study (SHCS) are Anag-
nostopoulos A, Battegay M, Bernasconi E, B€oni J, Braun DL,
Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G,
Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, G€unthard HF
(President of the SHCS), Haerry D (deputy of ‘Positive Council’),
Hasse B, Hirsch HH, Hoffmann M, H€osli I, Huber M, Kahlert CR
(Chairman of the Mother & Child Substudy), Kaiser L, Keiser O,
Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G,
Martinez de Tejada B, Marzolini C, Metzner KJ, M€uller N, Nicca
D, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the
Scientific Board), Rudin C, Scherrer AU (Head of Data Centre),
Schmid P, Speck R, St€ockle M (Chairman of the Clinical and Lab-
oratory Committee), Tarr P, Trkola A, Vernazza P, Wandeler G,
Weber R, Yerly S TBD.
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